002581 Stock Overview
Shandong Sinobioway Biomedicine Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Shandong Sinobioway Biomedicine Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.88 |
| 52 Week High | CN¥16.86 |
| 52 Week Low | CN¥7.79 |
| Beta | 0.080 |
| 11 Month Change | 4.39% |
| 3 Month Change | 44.17% |
| 1 Year Change | -27.38% |
| 33 Year Change | -34.69% |
| 5 Year Change | 82.21% |
| Change since IPO | -53.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002581 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.0% | -1.5% | -2.1% |
| 1Y | -27.4% | -9.4% | 2.8% |
Return vs Industry: 002581 underperformed the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 002581 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 002581 volatility | |
|---|---|
| 002581 Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002581 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002581's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 507 | Jialin Yue | www.sinobiowaymed.com.cn |
Shandong Sinobioway Biomedicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates in China. The company manufactures and supplies trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, and trimethyl acetate and its by-products. It also offers Anfulan, a human interferon a2b injection; Jiefu, a human interferon a2b spray; Enjingfu, a mouse nerve growth factor for injection; and Bellaph, a combined hepatitis A and B vaccine.
Shandong Sinobioway Biomedicine Co., Ltd. Fundamentals Summary
| 002581 fundamental statistics | |
|---|---|
| Market cap | CN¥7.84b |
| Earnings (TTM) | -CN¥347.55m |
| Revenue (TTM) | CN¥406.15m |
19.3x
P/S Ratio-22.6x
P/E RatioIs 002581 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002581 income statement (TTM) | |
|---|---|
| Revenue | CN¥406.15m |
| Cost of Revenue | CN¥91.72m |
| Gross Profit | CN¥314.43m |
| Other Expenses | CN¥661.98m |
| Earnings | -CN¥347.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 77.42% |
| Net Profit Margin | -85.57% |
| Debt/Equity Ratio | 0% |
How did 002581 perform over the long term?
See historical performance and comparison